<DOC>
	<DOCNO>NCT01245569</DOCNO>
	<brief_summary>The purpose present study determine effect health status spirometric value Foster® 100/6 ( two puff b.i.d . ) versus Seretide® 500/50 ( one inhalation b.i.d . ) , 12-week treatment period Chronic Obstructive Pulmonary Disease ( COPD ) patient .</brief_summary>
	<brief_title>A Study Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>Chronic obstructive pulmonary disease ( COPD ) incurable , debilitate progressive disease fatal . The recent Global Burden Disease Study rank COPD 6th lead cause mortality 12th lead cause morbidity world-wide . Furthermore , trend use medical care resource indicate economic cost COPD continue rise direct relation age population , increase prevalence disease cost new exist medical public health intervention .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . Male female patient age ≥ 40 year , sign Informed Consent form prior initiation studyrelated procedure applicable write informed consent obtain legal representative . 2 . Outpatients diagnosis COPD include : 1 . Smoking history least 10 pack year define [ ( number cigarette smoke per day ) x ( number year smoke ) / 20 ] , current exsmokers eligible . 2 . Use bronchodilator previous 2 month visit 1 . 3 . Postbronchodilator FEV1 &lt; 60 % predict normal value . 4 . Postbronchodilator FEV1/FVC &lt; 0.7 . 5 . A ≥ 5 % response reversibility test . 6 . A Baseline Dyspnoea Index ( BDI ) focal score less equal 10 ( meet also visit 2 ) . 3 . History one COPD exacerbation previous 12 month ( without consider last 2 month ) visit 1 . 4 . A cooperative attitude ability train proper use pMDI DPI ( Accuhaler® , circular mould plastic inhaler ) inhaler . Main 1 . Clinically relevant respiratory disorder . 2 . Current diagnosis asthma respiratory disorder COPD . 3 . Clinically significant laboratory ECG abnormalities indicate significant unstable concomitant disease may impact feasibility result study accord investigator 's judgement . 4 . Patients COPD exacerbation 2 month prior screen study period . 5 . Patients require long term ( least 12 hour daily ) oxygen therapy chronic hypoxemia . 6 . Patients treat depot corticosteroid 2 month precede visit 1 runin period .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>